In new drug development, demonstrating a clinically important effect of the new drug is a key element of efficacy evaluations instead of simply showing a statistical significance. However, approaches to demonstrate clinically important effects are unclear and not well recognized among many investigators and sponsors. The minimal clinically important change from baseline (MCIC) and minimal clinically important difference between groups (MCID) are used to assess the clinically important effect.
We state the roles of MCIC and MCID in each phase of new drug development and common approaches to establishing MCIC and MCID. Furthermore, we provide some common approaches on how to practically compare the clinical trial results with the MCIC and MCID and interpret the clinical importance from applications in new drug development. We also suggest incorporating the clinical importance at the planning phase of trials.
Clinically important effect Minimum clinically important change Minimum clinically important difference Clinical meaningfulness Drug effect
This is a preview of subscription content, log in to check access.
Jennison C, Turnbull BW. Effcient group sequential designs when there are several effect sizes under consideration. Stat Med. 2006;25: 917–932.CrossRefGoogle Scholar
Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Rahway, NJ: Erlbaum; 1988.Google Scholar
Make B. How can we assess outcomes of clinical trials: the MCID approach. J Chron Obstruct Pulm-on Dis. 2007;4:191–194.CrossRefGoogle Scholar
Sierevelt IN, Oldenrijk J, Poolman RW. Is statistical significance clinically important? A guide to judge the clinical relevance of study fndings. J Long-Term Effects Med Implants. 2007;17(2):173–179.CrossRefGoogle Scholar
Farrar JT, Young J P, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;149–158.Google Scholar
Burback D, Molnar FJ, John PS, Man-Son-Hing M. Key methodological features of randomized controlled trials of Alzheimer’s disease. Dement Geriatr Cogn Disord. 1999;10:534–540.CrossRefGoogle Scholar
Man-Son-Hing M, Laupacis A, O’Rourke K, et al. Determination of the clinical importance of study results. J Gen Intern Med. 2002;17:469–476.CrossRefGoogle Scholar